Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jun 25;44(24):2231-2233.
doi: 10.1093/eurheartj/ehad282.

SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world

Nikolaus Marx  1 , Dirk Müller-Wieland  1
Affiliations
Editorial

SGLT2 inhibitors in heart failure and type 2 diabetes: from efficacy in trials towards effectiveness in the real world

Nikolaus Marx et al. Eur Heart J. .

Abstract

Effect of SGLT2 inhibitors in patients with heart failure and type 2 diabetes. CV, cardiovascular; HF, heart failure.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest N.M. has given lectures for Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk; has received unrestricted research grants from Boehringer Ingelheim, and has served as an advisor for Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, and NovoNordisk. In addition, he has served in trial leadership for Boehringer Ingelheim and NovoNordisk. N.M. declines all personal compensation from pharma or device companies. D.M.W. has given lectures for Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, MSD, Novartis, Novo Nordisk, and Sanofi; and served as an advisor for Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, MSD, Novartis, Novo Nordisk, and Sanofi.

Figures

Graphical Abstract
Graphical Abstract
Effect of SGLT2 inhibitors in patients with heart failure and type 2 diabetes. CV, cardiovascular; HF, heart failure.
See this image and copyright information in PMC

Comment on

References

    1. Saturni S, Bellini F, Braido F, Paggiaro P, Sanduzzi A, Scichilone N, et al. . Randomized controlled trials and real life studies. Approaches and methodologies: a clinical point of view. Pulm Pharmacol Ther 2014;27:129–138. 10.1016/j.pupt.2014.01.005 - DOI - PubMed
    1. Walker E, Hernandez AV, Kattan MW. Meta-analysis: its strengths and limitations. Cleve Clin J Med 2008;75:431–439. 10.3949/ccjm.75.6.431 - DOI - PubMed
    1. Schilsky RL. Finding the evidence in real-world evidence: moving from data to information to knowledge. J Am Coll Surg 2017;224:1–7. 10.1016/j.jamcollsurg.2016.10.025 - DOI - PubMed
    1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128. 10.1056/NEJMoa1504720 - DOI - PubMed
    1. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. . Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–357. 10.1056/NEJMoa1812389 - DOI - PubMed

LinkOut - more resources